Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 3.91
IPCI's Cash to Debt is ranked higher than
50% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. IPCI: 3.91 )
IPCI' s 10-Year Cash to Debt Range
Min: 0.35   Max: No Debt
Current: 3.91

Equity to Asset 0.66
IPCI's Equity to Asset is ranked lower than
54% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IPCI: 0.66 )
IPCI' s 10-Year Equity to Asset Range
Min: -1.36   Max: 1
Current: 0.66

-1.36
1
F-Score: 5
Z-Score: 7.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -446.56
IPCI's Operating margin (%) is ranked higher than
58% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. IPCI: -446.56 )
IPCI' s 10-Year Operating margin (%) Range
Min: -1046100   Max: -414.8
Current: -446.56

-1046100
-414.8
Net-margin (%) -752.78
IPCI's Net-margin (%) is ranked higher than
55% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. IPCI: -752.78 )
IPCI' s 10-Year Net-margin (%) Range
Min: -914800   Max: -394.86
Current: -752.78

-914800
-394.86
ROA (%) -262.44
IPCI's ROA (%) is ranked lower than
53% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. IPCI: -262.44 )
IPCI' s 10-Year ROA (%) Range
Min: -262.44   Max: -22.22
Current: -262.44

-262.44
-22.22
ROC (Joel Greenblatt) (%) -553.94
IPCI's ROC (Joel Greenblatt) (%) is ranked higher than
66% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. IPCI: -553.94 )
IPCI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -104630.77   Max: -553.94
Current: -553.94

-104630.77
-553.94
Revenue Growth (%) -14.90
IPCI's Revenue Growth (%) is ranked higher than
66% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. IPCI: -14.90 )
IPCI' s 10-Year Revenue Growth (%) Range
Min: 0   Max: -14.9
Current: -14.9

EBITDA Growth (%) 0.60
IPCI's EBITDA Growth (%) is ranked higher than
82% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. IPCI: 0.60 )
IPCI' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 59.3
Current: 0.6

0
59.3
EPS Growth (%) 3.10
IPCI's EPS Growth (%) is ranked higher than
84% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. IPCI: 3.10 )
IPCI' s 10-Year EPS Growth (%) Range
Min: 0   Max: 80.2
Current: 3.1

0
80.2
» IPCI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with IPCI



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.80
IPCI's P/B is ranked lower than
73% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. IPCI: 11.80 )
IPCI' s 10-Year P/B Range
Min: 6.59   Max: 16.33
Current: 11.8

6.59
16.33
P/S 13.11
IPCI's P/S is ranked higher than
50% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. IPCI: 13.11 )
IPCI' s 10-Year P/S Range
Min: 13.11   Max: 169.5
Current: 13.11

13.11
169.5

Valuation & Return

vs
industry
vs
history
Forward Rate of Return (Yacktman) -85.04
IPCI's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. IPCI: -85.04 )
IPCI' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -85.04

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:I.Canada, I4A.Germany
IntelliPharmaCeutics International, Inc., was incorporated under the Canada Business Corporations Act by certificate and articles of arrangement dated October 22, 2009. The Company is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Controlled-release means releasing a drug into the bloodstream or at a target site in the body, over an extended period of time or at predetermined times. The Company's has developed drug delivery technology systems, based on the Hypermatrix platform, that facilitate controlled-release delivery of a range of pharmaceuticals. The Company's technology has been incorporated in drugs manufactured and sold by major pharmaceutical companies. The Company's platform of Hypermatrix drug delivery technologies include, but are not limited to, IntelliFoam, IntelliGITransporter, IntelliMatrix, IntelliOsmotics, IntelliPaste, IntelliPellets, and IntelliShuttle. These technologies provide a range of release profiles, taking into account the physical and chemical characteristics of a drug product, the therapeutic use of the particular drug, and the optimal site for release of the API in the gastrointestinal tract ('GIT'). It has a pipeline of products in various stages of development in therapeutic areas, including neurology, cardiovascular, and gastrointestinal tract, pain, and infection. The Company's competitors include medical technology, pharmaceutical, biotechnology and other companies, universities and research institutions. The research and development, manufacture and marketing of controlled-release pharmaceuticals are subject to regulation by U.S., Canadian and other governmental authorities and agencies.
» More Articles for NAS:IPCI

Headlines

Articles On GuruFocus.com
No related article found.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide